🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being viewed as a "major milestone" in the effort against increasingly resistant strains of the bacteria, according to health experts.

A Global Public Health Issue

Gonorrhoea infections are increasing worldwide, with data suggesting over 82 million infections each year. Notably increased rates are seen in the African continent and nations within the World Health Organization's Western Pacific region, which encompasses China and Mongolia to New Zealand. Across England, cases have hit a all-time high, while rates across Europe in 2023 were three times higher compared to figures for 2014.

“The clearance of novel therapies for gonorrhoea is an important and timely development in the context of growing infection rates, escalating drug resistance and the highly restricted available drugs at this time.”

Public health authorities are deeply concerned about the increase in antibiotic-resistant strains. The global health body has listed it as a "priority pathogen". Ongoing monitoring revealed that resistance to primary antibiotics like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Drugs Receive Authorization

Zoliflodacin, marketed under the name a brand name, was approved by the US Food and Drug Administration in recent days for combating gonorrhoea. This STI can lead to major issues, including the inability to conceive. Scientists believe that focused deployment of this new drug will help delay the spread of drug resistance.

Gepotidacin, developed by the pharmaceutical company GlaxoSmithKline, also received approval in concurrent days. This drug, which is additionally indicated for UTIs, was shown in trials to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Unique Development Model

This new treatment emerged from a unique collaborative effort for antibiotic development. The charitable organization GARDP partnered with the pharmaceutical company its industry partner to develop it.

“This approval represents a major breakthrough in the therapy of superbug gonorrhoea, which until now has been evolving faster than medical innovation.”

Clinical Trial Data and Worldwide Availability

According to results published in a major medical journal, the new drug eradicated the vast majority of uncomplicated infections. This establishes an equal footing with the typical regimen, which combines a dual-drug approach. The trial included hundreds of participants from several countries including the United States, Thailand, South Africa, and European nations.

Under the terms of its collaboration, GARDP has the rights to make available and distribute the drug in numerous developing nations.

Doctors on the front lines have voiced positive views. Having a one-pill regimen such as this is described as a "revolutionary step" for gonorrhoea control. This is considered vital to alleviate the strain of the illness for patients and to halt the transmission of highly drug-resistant gonorrhoea around the world.